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Abstract
Acute ischemic stroke is a major cause of morbidity 
and mortality in industrialized nations. The sequel of 
stroke ranges from mild to severe disability and even 
death. Since the impairment may be permanent, the 
costs to society from work incapacity and the need for 
long-term care can be high. Additionally, the burden of 
suffering associated with the disease may have devas-
tating effects on individuals and families. 
Following the occlusion of a cerebral vessel, the 
full extent of the infarction may not become clinically 
and radiologically apparent until days after. By then, 
the surrounding watershed zone, or penumbra, either 
survives or succumbs to necrosis over time. The natural 
history of this “tissue at risk” is determined by two fac-
tors: the collateralization from other vascular territo-
ries and the possible occurrence of spontaneous re-
canalization of the occluded vessel. The current treat-
ment options for acute ischemic stroke are aiming at 
an early and sustained restoration of flow to the pen-
umbra. The effect of the treatment is therefore 
time-dependent and the neurologic outcome is a func-
tion of the time span between onset of symptoms and 
recanalization therapy as well as of the recanalization 
rate associated with a specific treatment.
This report summarizes the results of the major 
trials on catheter-based interventions, either using 
thrombolytic drugs or novel mechanical approaches 
being developed to treat patients with acute ischemic 
stroke.
Akuter zerebrovaskulärer Insult: Gegenwart und Zukunft katheterbasierter Eingriffe
Zusammenfassung
Der akute ischämische zerebrovaskuläre Insult ist in 
den westlichen Industrieländern eine der häufigsten 
Ursachen von Morbidität und Mortalität. Die Folgen 
des Insults reichen für den Betroffenen von milden 
neurologischen Ausfällen über schwerste Pflegebe-
dürftigkeit bis zum Tod mit erheblichen Kosten für das 
Gesundheitssystem.
Nach einem akuten Verschluss eines hirnversor-
genden Gefäßes werden Teile des Parenchyms zunächst 
über Kollateralen vor der Nekrose bewahrt. Im Laufe von 
Tagen kann sich dieses Gewebe, die Penumbra, regene-
rieren, oder es wird untergehen. Dies ist sowohl von der 
Kollateralversorgung des Gewebes als auch von einer 
Reperfusion, z.B. durch spontane Thrombolyse, abhän-
gig. Das Ziel der derzeitigen Therapieoptionen ist eine 
Wiederherstellung der Perfusion der Penumbra durch 
Rekanalisierung des Gefäßes. Der Therapieerfolg hängt 
dabei von der Rekanalisierungsrate und der Ischämie-
zeit der Penumbra bis zur Reperfusion ab.
Dieser Artikel fasst die Ergebnisse der größeren 
Studien zu katheterbasierten Techniken zusammen 
und vergleicht die medikamentöse Thrombolyse mit 
neueren mechanischen Ansätzen zur Thrombektomie 
in der Behandlung des akuten ischämischen zerebro-
vaskulären Insults.
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Introduction
Acute ischemic cerebrovascular stroke is character-
ized by neurologic deterioration caused by the sud-
den occlusion of a brain-perfusing artery either by an 
embolic occlusion with thrombotic material or, less 
often, by a locally formed thrombus. The subsequent 
undersupply with oxygen (ischemia) causes a pro-
gressive damage of the brain tissue distally to the oc-
clusion site. Acute ischemic stroke is a common dis-
ease in industrialized nations, characterized by a high 
prevalence of cardiovascular risk factors and a pro-
gressive aging of the population. The natural course 
of stroke ranges from mild neurologic deficits to life-
long disability and dependency or death.
To protect patients from the high rate of morbid-
ity and mortality associated with stroke, various sys-
temic and local treatment options have been advo-
cated. 
Despite different approaches in the treatment 
strategy, all studies have underlined the crucial deter-
minants for the patients’ neurologic outcome after 
acute ischemic stroke [1–5]: 
(a)  the size of the ischemic brain area perfused by the 
occluded vessel; 
(b)  the time span between onset of symptoms and re-
vascularization; 
(c)  the recanalization rate associated with a specific 
treatment;
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(d)  the occurrence of symptomatic intracranial hem-
orrhage (sICH).
Hence, fast and sufficient reperfusion in combina-
tion with a low rate of sICH is the key to successful 
stroke treatment (Figures 1 and 2).
The intravenous administration of thrombo-
lytic drugs (intravenous thrombolysis [IVT]) has 
been evaluated in various randomized studies ap-
plying recombinant tissue-type plasminogen acti-
vator (rtPA) to acute ischemic stroke patients [3, 
6, 7]. The NINDS study [3, 6] was able to demon-
strate the efficacy of systemic IVT therapy when 
initiated within 3 h from onset of stroke symptoms 
and if an intracranial hemorrhage was previously 
ruled out. The IVT has been permitted in the USA 
since 1996. All thrombolytic therapies elevate the 
risk of bleeding. In the trials, in 6.4% (NINDS) to 
8.8% (ECASS) of patients with IVT an sICH oc-
curred.
Because of the narrow time window for treat-
ment and multiple exclusion criteria, only 9–22% of 
ischemic stroke patients admitted to stroke centers 
may be treated with IVT.
In addition, a reanalysis of the NINDS study 
[8] revealed the limited effect of IVT in patients 
with severe stroke (National Institute of Health 
Stroke Scale [NIHSS] > 16). The NIHSS increases 
with the size of the vessel occluded. An NIHSS 
> 12 suggests an occlusion of a proximal, large ves-
sel and therefore a high thrombus burden [9]. 
Figures 1a to 1f. Endovascular recanalization of an acute 
right-sided M1 occlusion in a 59-year-old patient. The initial 
ICA angiogram in anteroposterior (a) and lateral (b) projec-
tion demonstrates the complete M1 occlusion of the right 
MCA (➝). The extent of the occlusion can be angiographi-
cally demonstrated (c) by passing the thrombus in the MCA 
and injecting contrast (*). During retrieval of the microcath-
eter, contrast injection illustrates the proximal and distal 
end of the thrombus (d, **). After treatment, the target ves-
sel (M1) is completely recanalized (TIMI 3, e), but thrombotic 
material is dislodged into the proximal M2 segments (f), hin-
dering reperfusion of the complete MCA territory (➩). This 
distal dislocation is not assessed by the TIMI classification 
but relevant for the reperfusion success of the therapy. Some 
studies therefore additionally apply the Mori classification 
to document reperfusion.
Abbildungen 1a bis 1f. Endovaskuläre Rekanalisation eines 
akuten M1-Verschlusses links bei einem 59-jährigen Pati-
enten. Das initiale Angiogramm in frontaler (a) und lateraler 
(b) Projektion bestätigt den kompletten Verschluss (➝). Die 
Ausdehnung des Verschlusses kann nach Passage des 
Thrombus mit einem Mikrokatheter dargestellt werden (c). 
Dabei wird Kontrastmittel distal (*) und proximal (d, **) des 
Thrombus appliziert. Nach Therapie ist das Hauptgefäß (M1) 
komplett rekanalisiert (e), aber thrombotisches Material ist 
in einzelne M2-Segmente disloziert (f) und verhindert die 
Reperfusion in Teilen des abhängigen Stromgebiets (➩). Die 
Verschleppung von Thrombus nach distal wird von der 
TIMI-Klassifikation nicht berücksichtigt, ist aber für die zere-
brale Reperfusion relevant. Aus diesem Grund verwenden 
einige Studie zusätzlich die Mori-Klassifikation.
a b
c d
e f
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These data indicate a large room for further im-
provement in the treatment strategy and patient 
selection.
Endovascular Approaches
The local intraarterial techniques expand the time 
window for treatment and may increase the recanali-
zation rate compared to the systemic IVT. The local 
approach is promising to reduce or eliminate the ex-
posure to thrombolytic drugs and therefore to reduce 
the risk of accompanying hemorrhage. Various endo-
vascular treatment options including a range of phar-
macological and mechanical approaches have been 
advocated.
Intraarterial Thrombolysis
In intraarterial thrombolysis (IAT), a microcathe-
ter is placed proximal to or directly into the throm-
bus. Technically, a long 7-French (F) sheath is 
placed into the femoral artery and a 6- or 7-F guid-
ing catheter is advanced into the internal carotid 
artery (ICA) or vertebral artery of the affected 
side. A microcatheter is then navigated to the oc-
clusion site over a microwire.
Theoretical advantages of this route of appli-
cation include: 
(a)  the angiographic evaluation reveals the precise 
occlusion site, the extent of collaterals and as-
sesses the grade of recanalization during treat-
ment; 
Figures 2a to 2f. Diffusion-weighted imaging (DWI) illus-
trates an infarction in the basal ganglia (a) on the left in a 
62-year-old male patient with acute onset of right-sided 
hemiparesis and dysphasia. Perfusion imaging (b) illustrates 
a reduced perfusion of the MCA territory with a large mis-
match between MR perfusion (b) and DWI (a). The angiogram 
confirms the complete (TIMI 0) left M1 occlusion (c). Despite 
the complete recanalization (TIMI 3) after 1,000,000 U of 
urokinase and mechanical disruption of the thrombus (d), 
the patient developed an sICH 10 h later (e, f).
Abbildungen 2a bis 2f. Die Diffusionswichtung (DWI) zeigt 
einen linksseitigen Basalganglieninfarkt (a) bei einem 
62-jährigen Patienten mit akut aufgetretener rechtsseitiger 
Hemiparese und Dysphasie. Die Perfusionsbildgebung (b) 
beweist die Minderversorgung des Arteria-cerebri-media-
Stromgebiets mit ausgedehnter Diskrepanz zwischen MR-
Perfusion (b) und DWI (a). Das Angiogramm bestätigt den 
kompletten M1-Verschluss links (c). Trotz kompletter Reka-
nalisierung des Gefäßes nach lokaler Gabe von 1 000 000 
Einheiten Urokinase und mechanischer Manipulation des 
Thrombus (d) entwickelte der Patient 10 h später ein sym-
ptomatisches intrazerebrales Hämatom (e, f).
a b
c d
e f
Gralla J, et al. Future of Stroke Treatment
510 Herz 33 · 2008 · Nr. 7  © Urban & Vogel
(b)  a higher effective dosage of thrombolytic agent 
is delivered directly to the thrombus reducing 
the systemic side effects;
(c)  the approach facilitates the combination with 
the mechanical recanalization techniques.
In open clinical series IAT has achieved a higher 
early recanalization rate compared to IVT [10, 
11]. 
Down sides of IAT include:
(a)  it is a time-consuming procedure which delays 
the initiation of treatment compared to IVT;
(b)  it involves manipulation of cervical and cranial 
vessels with the risk of periinterventional com-
plications;
(c) it  demands highly specialized centers;
(d)  it requires high human and financial resources;
(e)  the direct endovascular access to the distal in-
tracranial vasculature, e.g., distal M2 and M3 
segments of the middle cerebral artery (MCA), 
is limited.
PROACT. The Prolyse in Acute Cerebral Throm-
boembolism I (PROACT I) study [5] was the first 
small clinical trial to evaluate the safety and effi-
ciency of intraarterial administration in the treat-
ment of acute ischemic stroke. The study included 
40 patients with an angiographically proven M1 or 
M2 occlusion and a mean of 5.5 h from symptom 
onset. 14 patients (mean NIHSS: 19) were random-
ized into the control placebo group, 26 patients 
(mean NIHSS: 17) were treated with a local admin-
istration of prourokinase (6 mg) over 120 min into 
the proximal thrombus surface. Any mechanical 
manipulation of the clot was not allowed. The re-
canalization was graded according to the Throm-
bolysis in Myocardial Infarction (TIMI) classifica-
tion and revealed a partial or complete recanaliza-
tion (TIMI 2 and 3) in 57.7% of the patients treated 
with prourokinase compared to 14.3% in the con-
trol group. An sICH within 24 h occurred in 15.5% 
of the treated patients and 7.1% of the placebo pa-
tients. The number of patients was too small to 
demonstrate a statistically significant benefit in 
terms of clinical outcomes or mortality at 90 days. 
Nevertheless, an absolute increase in favorable 
clinical neurologic outcome over the placebo group 
was found in 10–12%. The mortality rate was de-
creased from 42.9% in the placebo group to 26.9% 
in the prourokinase group. The results of PRO-
ACT I suggested an enhanced recanalization with 
prourokinase and a positive trend toward better 
neurologic outcome and survival rate.
The following large-scale, multicenter, random-
ized trial PROACT II [4] included 180 patients 
with angiographically confirmed M1 or M2 occlu-
sion within the first 6 h after onset of symptoms. 
121 patients (NIHSS: 17) received low-dose intra-
venous heparin (2,000 U bolus, 500 U/h) and intra-
arterial prourokinase (9 mg) proximally to the 
thrombus; again, any mechanical disruption of the 
thrombus was not allowed. 59 patients of the con-
trol group received only low-dose intravenous hep-
arin.
The intraarterially treated group showed a sig-
nificantly (p < 0.001) higher rate of partial or com-
plete recanalization in 66% compared to 18% in 
the heparin-only group. Excellent neurologic out-
come was achieved in 40% of the treated patients 
compared to 25% in the control group (p = 0.04). 
The rate of sICH within 24 h was elevated to 10% 
in the prourokinase group compared to 2% in the 
control group (p = 0.06), but no significant differ-
ence in the 90-day mortality was found (25% in the 
treated and 27% in the control group).
The study was able to demonstrate the benefi-
cial effect of IAT on the recanalization and clinical 
outcome of patients with M1 and M2 occlusions.
Single-center experiences. However, nonrandom-
ized single-center studies have reported on a high 
number of patients treated with IAT for acute isch-
emic stroke. The largest study of Brekenfeld et al. 
[12] reported a retrospective analysis of 297 stroke 
patients treated with intraarterial urokinase within 
a 6-h time window for occlusions in the anterior 
and posterior circulation. Contrary to the PRO-
ACT study protocol, the administration of throm-
bolytics was not limited to the proximal surface of 
the occlusion site but allowed application within 
the thrombus. In addition, mechanical manipula-
tion with the microwire and/or microcatheter was 
performed. The evaluated cohort had, compared to 
PROACT II, a longer median time span from 
symptom onset to treatment (318 vs. 255 min) and 
a slightly lower mean NIHSS (15 vs. 17). In this 
study, the mean dose of urokinase administered lo-
cally was 1,000,000 U. The study demonstrated a 
higher recanalization rate (TIMI 2 and 3) of 70% 
(vs. 66% in PROACT II) and a lower rate of sICH 
of only 4.8% (vs. 10% in PROACT II). A failed 
reperfusion was identified as independent predic-
tor of sICH. In patients with sICH a favorable clin-
ical outcome (modified Rankin Score [mRS]: 0–2) 
was less likely compared to the group of patients 
without sICH (7% vs. 58%).
The study illustrated a favorable outcome of 
stroke patients treated with IAT despite the de-
layed time to treatment in that group. The recana-
lization rate was higher compared to other studies 
on IAT probably due to the mechanical manipula-
tion of the thrombus performed by highly experi-
enced operators.
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Comparison IVT versus IAT
In many centers, accessible occlusions in the anteri-
or circulation are treated with IAT, either in patients 
who did not reperfuse after IVT or even as a first 
line of treatment. However, there is no randomized 
trial comparing patients’ outcome after IVT and 
IAT.
A recent publication compared the outcome 
and morbidity of patients treated with IVT and IAT 
in two different stroke units [11]. The patients were 
selected by the presence of a hyperdense MCA sign 
on computed tomography, indicating an M1 occlu-
sion. 55 patients were treated with IAT using uroki-
nase, 59 patients underwent IVT. Although the time 
to treatment was significantly (p = 0.0001) longer in 
the IAT group (mean 244 min) than in the IVT 
group (mean 156 min), the study revealed a more 
frequent favorable outcome for the patients treated 
with urokinase (53%) compared to the patients 
treated with IVT (23%; p = 0.001). In addition, the 
mortality rate was reduced (4.7%) in the IAT group 
compared to the IVT group (23%; p = 0.001).
Although these studies suggest a benefit for 
IAT over IVT especially for large vessel occlusions 
in the anterior circulation, there is a need for more 
data on both approaches. Other possibilities for im-
proving ischemic stroke therapy are the expansion 
of the time window using magnetic resonance imag-
ing selection criteria for treatment (e.g., presence of 
a large penumbra) and the use of combined IVT and 
IAT, the so-called bridging concept [13].
Ischemic Stroke in the Posterior 
Circulation
The data on IVT and IAT presented focuses on the 
most common site of intracranial vessel occlusion, 
the carotid distribution and the M1 and M2 seg-
ments of the MCA in particular. Posterior circula-
tion stroke, however, differs in several aspects. The 
evolution of clinical symptoms is often gradual. 
The precise assessment of the onset of symptoms 
and of the time window for treatment is difficult. 
Compared to ischemic stroke in the ICA territory, 
stroke in the posterior circulation is more often 
based on atherosclerotic disease (e.g., ruptured 
plaque) of the vasculature and locally formed 
thrombus. The risk of reocclusion after recanaliza-
tion is therefore higher [14–17]. The natural history 
shows a poor outcome with a high mortality rate of 
70–80% [14, 18]. Studies have suggested to extend 
the time window for treatment beyond the 6 h up to 
24 h [16, 19, 20]. However, no randomized trial of 
IAT has been carried out to support this practice. 
In clinical practice, there is no consensus on the 
strategy and time window  for treatment. However, 
recanalization is crucial to improve the dismal out-
come of patients with vertebrobasilar stroke. 
Therefore, the use of more aggressive treatment 
options such as extending the time window for the 
administration of thrombolytic drugs or mechani-
cal approaches seem justified.
Mechanical Recanalization Techniques
Although thrombolysis is effective in some patients, 
the limited recanalization rate and the increase of 
complications give room for further improvement in 
the strategy of stroke treatment. Recent develop-
ments focused on the possibilities of a mechanical 
recanalization in order to reduce revascularization 
time and to increase revascularization rate. Further-
more, the waiving of thrombolytic drugs is considered 
to reduce the occurrence of sICH and might prolong 
the time window for treatment, especially in the ICA 
territory.
Mechanical Thrombectomy
Intraarterial mechanical thrombectomy, in general, is 
a well-described procedure for peripheral vessels and 
first experiences are dated back to Fogarty in 1967 
[21]. In spite of the wide use in peripheral vessels the 
application of this method to treat cerebral vessel oc-
clusion is relatively new. Although the mechanical 
principles may be similar, the different composition 
of brain vessels as well as the possible fatal conse-
quences in case of thrombus dislocation or device 
failure and the lack of fast surgical alternatives de-
mand to adapt the principles of thrombectomy for the 
cerebral circulation.
Since 1999, descriptions of intracranial mechani-
cal thrombectomy are found in the literature [22]. 
Initial attempts consisted on the use of proximal de-
vices using a microcatheter for thrombus aspiration 
in combination with IAT [23, 24]. Since 2004, a few 
studies have reported on mechanical thrombectomy 
as a stand-alone therapy in acute stroke. This devel-
opment was mainly driven by the fast and innovative 
device improvement on a parallel field of cerebro-
vascular intervention, the intracranial aneurysm 
therapy. Since the ISAT trial [25, 26] stated a clear 
benefit in favor of endovascular treatment for intra-
cranial aneurysms, the spectrum of devices for intra-
cranial application has been broadened dramatically. 
Furthermore, the experiences of cardiology in acute 
myocardial infarction treatment have demonstrated 
the superiority of mechanical strategies compared 
with IVT.
As a consequence, also in the field of mechanical 
thrombectomy the use of more complex devices has 
been advocated recently. All mechanical thrombec-
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tomy devices are delivered by endovascular access 
proximal to the occlusion site.
The systems can be divided into two major groups 
according to where they apply force on the thrombus: 
(a)  Proximal devices apply force to the proximal base 
of the thrombus. This group includes various aspi-
ration catheters. 
(b)  Distal devices approach the thrombus proximally 
but then are advanced by guide wire and micro-
catheter across the thrombus to be unsheathed 
distally to it, where force is applied to the distal 
base of the thrombus. This group includes 
snare-like, basket-like or coil-like devices [27–
29]. 
Both approaches have been evaluated in an in vivo 
animal study [30]. The evaluation has demonstrated 
that proximal devices were faster in application with 
a low complication rate. The distal devices were more 
successful at removing thrombotic material, but their 
method of application and attendant thrombus com-
paction increases the risk of thromboembolic events 
and vasospasms [31].
The clinical success of the different approaches 
has been illustrated in multiple reports and small clin-
ical studies. So far, however, no randomized clinical 
data is available. This limits the comparison on the 
clinical effectiveness between different devices and 
to other therapies such as IVT and IAT.
Distal devices. Recent developments in mechanical 
stroke interventions mainly focus on the distal ap-
proach. Compared to IAT and the use of proximal 
devices and IAT, the procedure is technically more 
complex. Clinical observations have shown that 
thrombectomy with distal devices bears the risk of 
dislodging thrombotic material from the occlusion 
site into a previously unaffected vascular territory, 
e.g., from the MCA to the anterior cerebral artery. 
This embolic event then might worsen the patient’s 
symptoms. Therefore, distal devices are regularly 
used in combination with proximal balloon occlusion 
in the ICA in addition to aspiration from the guiding 
catheter to reduce this risk. Although the recommen-
dations differ with each device, in general, the proce-
dure is carried out as follows:
An 8- to 9-F sheath and balloon catheter of simi-
lar size are used. After placement of the balloon cath-
eter in the ICA, a microcatheter in combination with 
a microwire is navigated to the occlusion site. This 
catheter then has to pass the thrombus. In vivo stud-
ies [32, 33] as well as clinical observations suggest that 
the microcatheter passes between the thrombus and 
the vessel wall, rather than penetrating the thrombus. 
For some devices a contrast injection is recommend-
ed distally to the thrombus to estimate the length of 
occlusion and to illustrate the anatomy of the distal 
vessel. The device is then introduced into the micro-
catheter and unsheathed behind the thrombus. The 
balloon at the tip of the guiding catheter is inflated. 
During slow retraction of the device and mobilization 
of the thrombus, aspiration is applied at the guiding 
catheter. The device and thrombus are retrieved into 
the guiding catheter and the balloon is deflated. In 
clinical practice, the total procedure often has to be 
repeated to recanalize the vessel. Furthermore, the 
application of the balloon catheter might be limited 
in case of high-grade ICA stenosis.
Although the approach is similar for all distal de-
vices, the design and performance of the available 
device might differ significantly. Various different 
devices have been advocated; the following compila-
tion is an overview of the most frequently applied 
dedicated thrombectomy devices.
Catch device. The design of the Catch device 
(Balt, Montmorency, France) nicely illustrates the 
idea of the distal approach. The basket-like self-ex-
pandable device (Figure 3) is designed to mobilize 
and retrieve clot from cerebral vessels. It is available 
in different diameters (4 mm and 9 mm). To our 
knowledge, it was the first device obtaining the CE 
Figure 3. The bas-
ket-like Catch device is 
a self-expandable 
mesh that can easily be 
delivered distally to the 
thrombus. The distal 
devices shift the site of 
force effect to the dis-
tal surface of the 
thrombus.
Abbildung 3. Das 
Catch-Device besteht 
aus einem selbstex-
pandierenden Nitinol-
geflecht. Es wird hinter 
dem Thrombus freige-
setzt und übertragt die 
Kraft bei Zug auf den 
distalen Anteil des 
Thrombus.
Figures 4a and 4b. The 
Merci Retrieval System 
is available in various 
diameters and shapes. 
The corkscrew shape of 
the X-type (a) is slowly 
pulled back to encase 
the thrombus. The add-
ed microfilaments of 
the L-type (b) are de-
signed to reinforce this 
effect.
Abbildungen 4a und 
4b. Das schraubenar-
tige Merci-Retrieval-
System (Typ X, a) ist in 
verschiedenen Durch-
messern erhältlich und 
wird langsam von dis-
tal in den Thrombus 
gezogen, um diesen 
einzuhüllen. Das neue-
re Model (Typ L, b) ver-
fügt zusätzlich über 
Mikrofilamente, um 
diesen Effekt zu ver-
stärken.
a
b
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mark. The device has been successfully applied for 
thrombectomy in vitro, in vivo in animal studies and 
in clinical reports [32]. A registry for stroke patients 
treated with this device has been set up and clinical 
data on the recanalization rate and patients’ outcome 
after thrombectomy will be available in the near fu-
ture.
Merci device. The Merci Retrieval System (Con-
centric Medical, Inc., Mountain View, CA, USA) is a 
shaped wire constructed of nitinol. The flexible cork-
screw-like tip can easily be delivered through a mi-
crocatheter into the vessel distally to the occlusion 
site. When deployed, it returns to its coiled shape to 
ensnare the thrombus. The thrombus is bypassed and 
the retriever deployed from inside the catheter distal 
to the thrombus. The corkscrew-like tip is pulled back 
while being slowly rotated to ensnare the clot as a 
corkscrew would ensnare a cork. The retriever is then 
retracted into the catheter under proximal flow ar-
rest. Different versions of the device are available. 
The initial X-type (X6) consists of a bare-metal coil, 
the successor L-type applies additional filaments to 
increase the encasement of the clot (Figure 4). The 
devices are available in various diameters from 1.5 to 
3 mm depending on the treated vessel.
The Merci Retrieval System (X-type) is some-
how the protagonist of intracranial device develop-
ment. In 2004, the Food and Drug Administration 
(FDA) of the USA approved its use for clot removal 
from intracranial vessels in patients with ischemic 
stroke. The device was subsequently also CE-marked. 
This first approval has undoubtedly accelerated the 
whole commercial development of mechanical 
thrombectomy devices in the recent years.
FDA approval was based on a review of data 
obtained in the multicenter Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) trial that 
involved 141 patients (mean age: 60 years, mean 
NIHSS: 21) ineligible for standard thrombolytic ther-
apy [27]. The time window between onset of clinical 
symptoms and endovascular treatment was extended 
to 8 h, compared to the 6-h window usually aplied for 
IAT.
This trial reported a recanalization rate (TIMI 2 
and 3) using the X-type MERCI retriever of 46%. An 
sICH was found in 7.8% of the patients mainly follow-
ing ICA and MCA occlusions (90%). In the study, the 
number of attempts to retrieve the clot was limited to 
six; a mean of 2.9 attempts was performed for recanali-
zation. The mean procedural time was 2.1 h. With re-
spect to device-related complications the study report-
ed vessel perforations (4.2%), subarachnoid hemor-
rhages (2.1%) and embolization of thrombotic 
material (2.1%) [27, 28, 34].
The recently published Multi MERCI trial [35] 
was a prospective, multicenter, single-arm registry 
that included 131 patients (mean age: 68 years, mean 
NIHSS: 19) treated with different Merci Retrieval 
Systems (X5, X6, and the novel L5). Again, the time 
window between onset of clinical symptoms and en-
dovascular treatment was extended to 8 h and the 
majority of patients were treated for an ICA or MCA 
occlusion (92%). Patients with persistent large vessel 
occlusion after IVT (with rtPA) were also included in 
the study and adjunctive IAT using rtPA was al-
lowed.
In 55% of the interventions, the mechanical 
thrombectomy led to recanalization (TIMI 2 and 3). 
After adjunctive IAT 68% of the target vessels were 
recanalized. Clinically significant device-related com-
plications occurred in 5.5% and the rate of sICH was 
9.8%. At 90 days 36% of the patients had a favorable 
outcome (mRS: 0–2) and the mortality rate was 
34%.
Phenox device. An interesting new approach is 
the Phenox clot retriever (pCR, Phenox GmbH, Bo-
Figures 5a to 5c. The Phenox pCR device (a) applies force to the distal surface of the 
thrombus only by flexible polyamide microfilaments mounted on a core wire. This 
flexible device is applicable even in small side branches. The newly developed CRC 
device (b) additionally carries a self-expandable nitinol mesh on the proximal seg-
ment. When applied to the vessel, as simulated in a glass tube (c), the stent-like 
mesh extends and increases the force on the thrombus.
Abbildungen 5a bis 5c. Das Phenox-pCR-Device (a) verfügt lediglich über Mikrofi-
lamente, um Kraft auf den distalen Anteil des Thrombus auszuüben. Dieser flexi-
ble Aufbau erlaubt die Anwendung auch zur Behandlung von Verschlüssen in 
kleineren Seitenästen. Bei dem neueren CRC-Device (b) wurde zusätzlich proximal 
ein selbstexpandierendes Nitinolgeflecht aufgebracht. Im Gefäß freigesetzt, hier 
simuliert in einem Glasröhrchen (c), verstärkt dieses die Struktur des Device und 
somit die Kraftübertragung auf den Thrombus.
a
b
c
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chum, Germany, CE-marked). The pCR device re-
duces the stiff mechanical components and applies 
force to the distal surface of the thrombus by devel-
oping a dense palisade of perpendicular-oriented 
polyamide microfilaments mounted on a core wire 
(Figure 5a). This flexible design allows the use of two 
devices simultaneously (e.g., in bifurcations or larger 
vessels) and the microfilaments might be able to re-
duce distal emboli due to a filter effect [36]. The de-
vice is introduced into the target vessel through a 
0.021" or 0.027" microcatheter, deployed distally to 
the thrombus, and slowly pulled back under continu-
ous aspiration via the guiding catheter. Different di-
ameters and lengths are available (diameter: 2 mm 
proximally, 2–5 mm distally, length: 10–20 mm). The 
great flexibility of devices may allow to treat more 
distal branches of the intracranial vasculature such as 
M2 and M3 branches of the MCA.
The newly developed CRC version of the device 
(Figures 5b and 5c) applies additional force to the 
thrombus by an attached proximal self-expandable 
nitinol cage.
Few clinical reports on the use of the device in 
vitro and in clinical application are available [36, 37]. 
A clinical trial on 55 stroke patients has just been 
completed and the data will be published soon.
Proximal devices. From the procedural point of view, 
proximal devices are comparable to IAT. Access is 
usually gained with a 7- to 8-F sheath. After place-
ment of the guiding catheter, the device is navigated 
to the proximal surface of the clot. Force is applied to 
the thrombus either by aspiration and pulling of the 
catheter or in combination with mechanical disrup-
tion of the clot. This approach omits repetitive pass-
ing of the occlusion site.
Aspiration catheters. Simple aspiration devices 
are microcatheters, flexible enough to pass the tortu-
osity of cranial vessels (e.g., carotid siphon) and ex-
hibit a braiding that prevents collapse during aspira-
tion with, e.g., a 60-ml syringe. The diameter of these 
devices range between 4.5 and 5.5 F and they are 
equipped with a blunt tip. Only a few aspiration cath-
eters dedicated to intracranial occlusions are avail-
able and none of them has been systematically evalu-
ated in a clinical trial.
Vasco 35 Aspi microcatheter. Few clinical data is 
available on the Vasco 35 Aspi microcatheter (Balt, 
Montmorency, France). An in vivo animal study [32] 
has demonstrated the feasibility of clot retrieval using 
this device in the setting of acute vessel occlusion. 
Furthermore, the mechanically simple approach, 
avoiding the passage of the occlusion site, seems to be 
less traumatic to the vessel wall. The Vasco 35 Aspi is 
a 5-F braided catheter available with a preshaped 
curved tip. It allows easy navigation through the ca-
rotid siphon and has been applied for thrombus aspi-
ration in the MCA and ICA (Figure 6). Furthermore, 
it can be used in a triaxial system to advance larger 
guiding catheters into the intracranial ICA for fur-
ther aspiration and/or stenting [38].
Figures 6a to 6f. Complete distal M1 occlusion (➝) on the left side in a 71-year-old 
female patient (a, b). Although the carotid siphon exhibits a moderate elongation, 
a Vasco 35 aspiration catheter (*) is advanced into the proximal M1 segment (c, d). 
With aspiration (60-ml syringe), the thrombus is retrieved from the vessel result-
ing in a complete recanalization of the M1 segment (➩, TIMI 3, e, f).
Abbildungen 6a bis 6f. Kompletter linksseitiger M1-Verschluss (➝) bei einer 
71-jährigen Patientin (a, b). Der Karotissiphon erscheint etwas elongiert, dennoch 
kann der Vasco-35-Aspirationskatheter (*) problemlos in das proximale M1-Seg-
ment eingebracht werden. Unter Aspiration mit einer 60-ml-Spritze wird der 
Thrombus aus dem Gefäß entfernt und dieses somit komplett rekanalisiert (➩, 
TIMI 3, e, f).
a b
c d
e f
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Fragmentation and aspiration. The disadvantage 
of the aspiration catheters is the fragmentation of the 
thrombus while applying force to the proximal sur-
face of the clot. The fragment then obstructs the cath-
eter and hinders further aspiration and demands re-
trieval and repositioning of the catheter.
An further development of the aspiration tech-
nique is the controlled fragmentation and aspiration 
of the debris. Various more or less mechanically com-
plex devices have been tested experimentally in 
stroke models.
Penumbra device. The most remarkable and 
promising device of this group is the Penumbra Sys-
tem (Penumbra, Alameda, CA, USA). As the second 
device available, it has received both FDA and CE 
approval for use in the revascularization of patients 
with acute ischemic stroke.
The Penumbra System consists of a microcathe-
ter attached to continuous aspiration via a dedicated 
pumping system. A microwire/separator with an ol-
ive-shape tip is used to fragmentize the thrombus 
from proximally to distally (Figure 7). Both, micro-
catheter and separator are available in various sizes 
and diameters to adjust the device to different ana-
tomic settings.
A prospective, single-arm, independently moni-
tored trial was performed to assess the efficiency and 
safety of the system [39]. A total of 23 patients (mean 
age: 60 years, mean NIHSS: 21) were enrolled within 
8 h after onset of symptoms. Six patients included in 
the study were refractory to IVT. Unlike other stud-
ies on thrombectomy, a large number of patients had 
occlusions in the posterior circulation (43%). In nine 
patients additional IAT was performed using rtPA. 
In all patients (100%) the target vessel was recana-
lized (TIMI 2 or 3). The study did not exhibit any pro-
cedural complications. The high mortality rate (45%) 
is likely related to the patient population enrolled. 
An sICH occurred in 15% of the patients.
The reported recanalization rate underlines the 
potential of this approach.
Laser recanalization and Angiojet. Laser recana-
lization and intracranial application of the Angiojet 
device (Possis Medical, Inc., Minneapolis, MN, USA) 
have been investigated experimentally. Despite the 
potential advantages of the proximal approach with 
fragmentation and aspiration, the laser and Angiojet 
devices are not currently approved for the intracra-
nial circulation due to the rigidity of these mechani-
cally complex devices.
Study groups have tested laser recanalization, in 
which light absorption photo energy within the cath-
eter tip is changed into acoustic energy that emulsi-
fies the thrombus. Berlis et al. [40] tested the efficacy 
and safety of this method in 34 acute ischemic stroke 
patients. 18 patients were treated with laser recanali-
zation alone; in these 18 patients the recanalization 
rate was 61.1%. In 16 patients treatment was rated as 
incomplete because of vessel tortuosity, perforation, 
technical failure, or stenosis. Overall, the hemorrhage 
rate was 5.9%, the mortality 38.2%. Laser recanaliza-
tion had the decisive advantage of allowing fast re-
canalization within minutes (mean application time: 
9.65 min).
The Angiojet is a catheter designed to perform 
hemolytic thrombectomy based on the Venturi effect. 
In addition to the catheter, the system has a high-pres-
sure water pump to pump a saline solution in a 0.5-mm 
metal tube to the catheter tip. The catheter lumen is 
located in a 4-F catheter, whose main lumen is used to 
house the microwire and for aspiration. At the cathe-
ter tip water can be sprayed in small jets backward 
into the catheter, thus creating negative pressure that 
sucks in the endovascular thrombotic material and 
conveys it in a backflow out of the catheter. The poor 
flexibility of the first Angiojet catheter limited its use 
to segments of the large vessels supplying the brain. 
Nevertheless, this method has been successfully used 
to treat some patients with ICA occlusions or basilar 
artery thromboses [41]. A safety study of a smaller 
version of the Angiojet, designed to enable catheter-
ization of the MCA, was terminated early due to ves-
sel dissections. Modifications of both the catheter and 
Figure 7. The Penumbra System consists of a microcatheter 
for continuous aspiration and a separator, an olive-shaped 
corpus mounted on a flexible microwire. The manipulation 
of the thrombus via the proximal surface fragmentizes the 
thrombus. The continuous aspiration clears the debris from 
the vessel. The system is available in different sizes for inter-
ventions in cranial vessels of various diameters.
Abbildung 7. Das Penumbra-System besteht aus einem Mi-
krokatheter zur Applikation der kontinuierlichen Aspiration 
und einem Separator. Durch Vor- und Zurückziehen des Se-
parators wird der Thrombus fragmentiert und bei konstan-
ter Aspiration aus dem Gefäß entfernt. Das System ist in 
Größen für verschiedene Gefäße verfügbar.
Gralla J, et al. Future of Stroke Treatment
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the study protocol are currently undergoing evalua-
tion in a phase I trial, the Thrombectomy in Middle 
Cerebral Artery Embolism (TIME) study.
Other Mechanical Approaches
PTA and stent. The most recent approach adopts an 
angiologic/cardiologic procedure for the treatment of 
vessel occlusions known as percutaneous balloon an-
gioplasty (PTA), sometimes in combination with 
stent placement. By omitting the repetitive retrieval 
attempts needed for the mechanical thrombectomy, 
this approach may reduce severe complications and 
thromboembolic events.
PTA achieves fast recanalization of occluded 
vessels, while placement of the mesh stent stabilizes 
the result by pinning the thrombus to the vessel wall. 
This combined technique has a high recanalization 
rate in peripheral vessel and coronary occlusions and 
is considered a standard procedure in these cardio-
vascular territories. Therefore, it has great potential 
for achieving fast intracranial recanalization, since 
the pathophysiological background may be similar. 
Unlike peripheral or coronary vessels, however, in-
tracranial occlusions usually represent purely throm-
boembolic events without underlying stenosis. 
Moreover, the risks associated with intracranial in-
terventions are greater, since the patient can suffer 
permanent neurologic damage from vessel dissection 
or embolism. One of the main differences with the 
coronary circulation is the extremely thin wall of in-
tracranial vessels, which may favor vessel perfora-
tion. In addition, even a small residual thrombus bur-
den may jeopardize a sufficient recanalization or 
cause a permanent occlusion of perforating vessels. 
Therefore, to date combined PTA and stent place-
ment have not been routinely used to treat patients 
with acute ischemic stroke.
An in vivo animal study evaluated the recanali-
zation and complication rate of PTA and stenting in 
the setting of acute cerebrovascular occlusion [32]. 
The recanalization rate of PTA was not found to be 
sufficient for a stand-alone therapy in the treatment 
of acute ischemic stroke. Compared to stenting, the 
recanalization rate was significantly lower immedi-
ately after application as well as during the time 
course of the study (3-h observation interval). Fur-
thermore, PTA revealed a significantly lower and de-
creasing recanalization rate over time. By contrast, 
stent application in combination with postdilatation 
is a fast and safe option to restore permanent recana-
lization in the occluded vessel.
An ongoing study reports for the first time the 
use of intracranial stent placement in 19 patients with 
acute ischemic stroke in whom thrombolysis or me-
chanical recanalization attempts had been unsuccess-
ful [42]. The small study employs three different bal-
loon-mounted stent systems. The reported recanali-
zation rate was 79%, clearly superior to any other 
approach. The intracranial hemorrhage rate is 5% 
and mortality 32%.
Avoiding typical complications of thrombolysis 
and mechanical thrombectomy, this approach might 
have a high clinical potential.
Conclusion
Patients’ outcome after acute ischemic stroke de-
pends on the territory affected, the time span between 
onset of symptoms and revascularization, the recana-
lization rate of any specific revascularization strategy, 
and the occurrence of intracranial hemorrhage or 
major procedure-related complications. At present, 
in most of the centers, IVT or IAT are the standard 
treatment, sometimes combined in a bridging con-
cept.
Although being established, thrombolytic thera-
py is not effective in all patients, carries a risk of intra-
cranial hemorrhage, and has a limited time window 
for treatment. Current research therefore focuses on 
various mechanical revascularization techniques to 
achieve fast and sustained reperfusion. New-genera-
tion thrombolytic drugs are believed to reduce the 
incidence of symptomatic intracranial hemorrhage 
and prolong the time window for treatment. Initial 
clinical results on mechanical recanalization are en-
couraging, but more clinical data on the various dif-
ferent devices and approaches are necessary.
The future in the treatment of acute ischemic 
stroke is likely to be a combination of different me-
chanical and thrombolytic techniques, probably in a 
staged escalation concept.
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